- Home
- AMAT vs AZN Comparison
AMAT vs AZN Comparison
Compare AMAT & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AMAT | AZN |
|---|---|---|
| Founded | 1967 | 1992 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 239.4B | 285.7B |
| IPO Year | 1994 | N/A |
Fundamental Metrics
Financial Performance| Metric | AMAT | AZN |
|---|---|---|
| Price | $336.65 | $195.03 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 28 | 1 |
| Target Price | ★ $334.57 | N/A |
| AVG Volume (30 Days) | ★ 6.4M | 2.1M |
| Earning Date | 05-14-2026 | 01-01-0001 |
| Dividend Yield | 0.57% | ★ 1.65% |
| EPS Growth | ★ 0.58 | N/A |
| EPS | ★ 2.54 | N/A |
| Revenue | ★ $14,608,000,000.00 | N/A |
| Revenue This Year | $13.01 | $10.13 |
| Revenue Next Year | $19.66 | $6.21 |
| P/E Ratio | $128.52 | ★ $31.91 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $123.74 | $61.24 |
| 52 Week High | $395.95 | $212.71 |
Technical Indicators
Market Signals| Indicator | AMAT | AZN |
|---|---|---|
| Relative Strength Index (RSI) | 46.62 | 61.95 |
| Support Level | $311.07 | $89.28 |
| Resistance Level | $344.60 | $211.32 |
| Average True Range (ATR) | 13.64 | 3.38 |
| MACD | -6.63 | -5.22 |
| Stochastic Oscillator | 20.10 | 20.00 |
Price Performance
Historical ComparisonAbout AMAT Applied Materials Inc.
Applied Materials is the largest semiconductor wafer fabrication equipment manufacturer in the world. It has a broad portfolio spanning nearly every corner of the WFE ecosystem. Applied Materials holds leading market share in deposition, which entails the layering of new materials on semiconductor wafers. It is more exposed to general-purpose logic chips made at integrated device manufacturers and foundries. It counts the largest chipmakers in the world as customers, including TSMC, Intel, and Samsung.
About AZN AstraZeneca PLC
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.